JP7847852B2 - スプライシングを調節するための化合物及び方法 - Google Patents
スプライシングを調節するための化合物及び方法Info
- Publication number
- JP7847852B2 JP7847852B2 JP2022552208A JP2022552208A JP7847852B2 JP 7847852 B2 JP7847852 B2 JP 7847852B2 JP 2022552208 A JP2022552208 A JP 2022552208A JP 2022552208 A JP2022552208 A JP 2022552208A JP 7847852 B2 JP7847852 B2 JP 7847852B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- heteroaryl
- aryl
- alkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Replacement Of Web Rolls (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Psychology (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026060544A JP2026108831A (ja) | 2020-02-28 | 2026-04-01 | スプライシングを調節するための化合物及び方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062983541P | 2020-02-28 | 2020-02-28 | |
| US62/983,541 | 2020-02-28 | ||
| US202063007333P | 2020-04-08 | 2020-04-08 | |
| US63/007,333 | 2020-04-08 | ||
| US202063040484P | 2020-06-17 | 2020-06-17 | |
| US63/040,484 | 2020-06-17 | ||
| US202063072790P | 2020-08-31 | 2020-08-31 | |
| US63/072,790 | 2020-08-31 | ||
| US202063126492P | 2020-12-16 | 2020-12-16 | |
| US63/126,492 | 2020-12-16 | ||
| PCT/US2021/020153 WO2021174164A1 (en) | 2020-02-28 | 2021-02-28 | Compounds and methods for modulating splicing |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026060544A Division JP2026108831A (ja) | 2020-02-28 | 2026-04-01 | スプライシングを調節するための化合物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023515620A JP2023515620A (ja) | 2023-04-13 |
| JP2023515620A5 JP2023515620A5 (cg-RX-API-DMAC7.html) | 2025-08-22 |
| JP7847852B2 true JP7847852B2 (ja) | 2026-04-20 |
Family
ID=75143749
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552208A Active JP7847852B2 (ja) | 2020-02-28 | 2021-02-28 | スプライシングを調節するための化合物及び方法 |
| JP2022552209A Active JP7736700B2 (ja) | 2020-02-28 | 2021-02-28 | 複素環アミド及びスプライシングを調節するためのその使用 |
| JP2025142246A Pending JP2025172876A (ja) | 2020-02-28 | 2025-08-28 | 複素環アミド及びスプライシングを調節するためのその使用 |
| JP2026060544A Pending JP2026108831A (ja) | 2020-02-28 | 2026-04-01 | スプライシングを調節するための化合物及び方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552209A Active JP7736700B2 (ja) | 2020-02-28 | 2021-02-28 | 複素環アミド及びスプライシングを調節するためのその使用 |
| JP2025142246A Pending JP2025172876A (ja) | 2020-02-28 | 2025-08-28 | 複素環アミド及びスプライシングを調節するためのその使用 |
| JP2026060544A Pending JP2026108831A (ja) | 2020-02-28 | 2026-04-01 | スプライシングを調節するための化合物及び方法 |
Country Status (15)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024532422A (ja) * | 2021-08-30 | 2024-09-05 | リミックス セラピューティクス インコーポレイテッド | スプライシングを調整するための化合物及び方法 |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163541A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| IL297963A (en) | 2020-05-07 | 2023-01-01 | Adorx Therapeutics Ltd | Antagonists of the adenosine a2a receptor |
| WO2021231571A1 (en) | 2020-05-13 | 2021-11-18 | Chdi Foundation, Inc. | Htt modulators for treating huntington's disease |
| US12065427B2 (en) | 2021-04-29 | 2024-08-20 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds capable of activating STING |
| IL311135A (en) | 2021-08-30 | 2024-04-01 | Remix Therapeutics Inc | Compounds and methods for modulating splicing |
| AU2022394333A1 (en) * | 2021-11-17 | 2024-06-27 | Chdi Foundation, Inc. | HTT modulators for treating Huntington’s disease |
| CA3249778A1 (en) * | 2022-06-15 | 2023-12-21 | Ptc Therapeutics, Inc. | HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE |
| WO2024086569A1 (en) | 2022-10-17 | 2024-04-25 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| WO2024086570A1 (en) | 2022-10-17 | 2024-04-25 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| TW202440080A (zh) * | 2023-03-01 | 2024-10-16 | 美商雷密克斯醫療公司 | 用於調節剪接之化合物及方法 |
| WO2024182788A1 (en) * | 2023-03-01 | 2024-09-06 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| TW202535379A (zh) * | 2024-01-26 | 2025-09-16 | 大陸商成都微芯藥業有限公司 | Usp1抑制劑及其製備方法和用途 |
| CN118166099B (zh) * | 2024-02-05 | 2024-10-22 | 北京大学深圳医院 | 检测hsa_circ_0014088的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用 |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007091877A (ja) | 2005-09-29 | 2007-04-12 | Fujifilm Corp | ナフタロシアニン色素およびその製造方法 |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| JP2010500353A (ja) | 2006-08-08 | 2010-01-07 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | E1活性化酵素のインヒビターとして有用なヘテロアリール化合物 |
| JP2011513334A (ja) | 2008-02-29 | 2011-04-28 | ワイス・エルエルシー | ピラゾロ[1,5−a]ピリミジンの架橋二環式複素環式またはスピロ二環式複素環式誘導体、その調製方法および使用 |
| JP2011520941A (ja) | 2008-05-23 | 2011-07-21 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
| JP2012528194A (ja) | 2009-05-29 | 2012-11-12 | メルク・シャープ・アンド・ドーム・コーポレーション | C型肝炎などの疾患を処置するための3つの整列型アリール部分で構成された抗菌性化合物 |
| JP2013529658A (ja) | 2010-06-28 | 2013-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン |
| CN104341403A (zh) | 2014-10-10 | 2015-02-11 | 山东盛华电子新材料有限公司 | 一种2,5-二杂环取代萘基噁烷衍生物及其制备方法 |
| JP2015516424A (ja) | 2012-05-09 | 2015-06-11 | ゾエティス・エルエルシー | 駆虫剤としてのアゼチジン誘導体 |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| JP2016514134A (ja) | 2013-03-11 | 2016-05-19 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Betブロモドメイン阻害剤およびこれを用いる治療方法 |
| JP2016530231A (ja) | 2013-06-25 | 2016-09-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 脊髄性筋萎縮を処置するための化合物 |
| JP2017520570A (ja) | 2014-06-25 | 2017-07-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 脊髄性筋萎縮症を処置するためのイミダゾ[1,2−a]ピラジン−1−イルベンズアミド化合物 |
| WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| CN109180690A (zh) | 2018-10-15 | 2019-01-11 | 烟台显华化工科技有限公司 | 一类用作蓝色荧光材料的氮杂芳香化合物及其应用 |
| WO2019079649A1 (en) | 2017-10-18 | 2019-04-25 | Blueprint Medicines Corporation | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200808325A (en) | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
| WO2008040951A1 (en) | 2006-10-03 | 2008-04-10 | Astrazeneca Ab | Compounds |
| GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| US20110288089A1 (en) | 2009-01-22 | 2011-11-24 | Syngenta Crop Protection Llc | Insecticidal compounds |
| CN102020643A (zh) | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
| TW201202230A (en) * | 2010-05-24 | 2012-01-16 | Mitsubishi Tanabe Pharma Corp | Novel quinazoline compound |
| JP2012028440A (ja) | 2010-07-21 | 2012-02-09 | Hitachi Kokusai Electric Inc | 基板処理装置及び半導体装置の製造方法 |
| EP3406252B1 (en) | 2012-02-10 | 2020-05-13 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| KR20140125061A (ko) * | 2013-04-18 | 2014-10-28 | (주)경인양행 | 유기발광 화합물 및 이를 포함하는 유기전계발광소자 |
| US9862701B2 (en) | 2014-09-25 | 2018-01-09 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| NL2013636B1 (en) | 2014-10-15 | 2016-10-04 | Kraton Polymers Us Llc | An accelerator system, a composition comprisng a synthetic isoprene polymer and the accelerator system, and dipped goods made from the composition. |
| EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
| CN106220644B (zh) * | 2015-04-24 | 2020-07-31 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| JP2019535789A (ja) | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス,インコーポレーテッド | Rnaスプライシングを調節する方法 |
| EP3573954A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| EP4151627A1 (en) * | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| US20230152257A1 (en) | 2017-09-25 | 2023-05-18 | Skyhawk Therapeutics, Inc. | Methods and compositions for screening and identification of splicing |
| TW201942115A (zh) * | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| JP2021521200A (ja) | 2018-04-10 | 2021-08-26 | スカイホーク・セラピューティクス・インコーポレーテッド | 癌の処置のための化合物 |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020004594A1 (ja) * | 2018-06-27 | 2020-01-02 | 株式会社リボルナバイオサイエンス | 脊髄性筋萎縮症の予防または治療剤 |
| TWI834690B (zh) * | 2018-07-18 | 2024-03-11 | 美商富曼西公司 | 用於防治無脊椎動物害蟲之異噁唑啉化合物 |
| US12503467B2 (en) * | 2018-12-10 | 2025-12-23 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors |
| US20220081412A1 (en) * | 2018-12-20 | 2022-03-17 | The Regents Of The University Of Michigan | Quinolinyl-pyrazine-carboxamide compounds and uses thereof |
| KR20220012248A (ko) * | 2019-04-22 | 2022-02-03 | 베타 파머수티컬 컴퍼니 리미티드 | 퀴나졸린 화합물 및 이의 의약품에서의 응용 |
| WO2021007378A1 (en) * | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
-
2021
- 2021-02-28 AU AU2021228284A patent/AU2021228284A1/en active Pending
- 2021-02-28 EP EP21713823.9A patent/EP4110464A1/en active Pending
- 2021-02-28 US US17/802,833 patent/US20240190879A1/en active Pending
- 2021-02-28 AU AU2021228767A patent/AU2021228767A1/en active Pending
- 2021-02-28 WO PCT/US2021/020153 patent/WO2021174164A1/en not_active Ceased
- 2021-02-28 JP JP2022552208A patent/JP7847852B2/ja active Active
- 2021-02-28 KR KR1020227033660A patent/KR20220159386A/ko not_active Ceased
- 2021-02-28 CA CA3169691A patent/CA3169691A1/en active Pending
- 2021-02-28 MX MX2022010684A patent/MX2022010684A/es unknown
- 2021-02-28 US US17/802,863 patent/US20240226098A1/en active Pending
- 2021-02-28 IL IL295956A patent/IL295956A/en unknown
- 2021-02-28 US US17/802,719 patent/US20230365566A1/en active Pending
- 2021-02-28 CA CA3169709A patent/CA3169709A1/en active Pending
- 2021-02-28 BR BR112022017210A patent/BR112022017210A2/pt unknown
- 2021-02-28 JP JP2022552209A patent/JP7736700B2/ja active Active
- 2021-02-28 EP EP21713822.1A patent/EP4110785A1/en active Pending
- 2021-02-28 BR BR112022017188A patent/BR112022017188A2/pt unknown
- 2021-02-28 CN CN202180031467.0A patent/CN115485025A/zh active Pending
- 2021-02-28 EP EP21713824.7A patent/EP4110459A1/en active Pending
- 2021-02-28 CR CR20210483A patent/CR20210483A/es unknown
- 2021-02-28 WO PCT/US2021/020154 patent/WO2021174165A1/en not_active Ceased
- 2021-02-28 WO PCT/US2021/020152 patent/WO2021174163A1/en not_active Ceased
- 2021-02-28 IL IL295957A patent/IL295957A/en unknown
- 2021-02-28 CN CN202180030671.0A patent/CN115515679A/zh active Pending
- 2021-02-28 MX MX2022010683A patent/MX2022010683A/es unknown
- 2021-02-28 KR KR1020227033663A patent/KR20220158238A/ko not_active Ceased
- 2021-02-28 CR CR20220484A patent/CR20220484A/es unknown
-
2022
- 2022-08-26 CL CL2022002342A patent/CL2022002342A1/es unknown
- 2022-08-26 CL CL2022002341A patent/CL2022002341A1/es unknown
- 2022-08-28 SA SA522440338A patent/SA522440338B1/ar unknown
- 2022-09-27 CO CONC2022/0013832A patent/CO2022013832A2/es unknown
- 2022-09-27 CO CONC2022/0013827A patent/CO2022013827A2/es unknown
-
2025
- 2025-08-28 JP JP2025142246A patent/JP2025172876A/ja active Pending
-
2026
- 2026-04-01 JP JP2026060544A patent/JP2026108831A/ja active Pending
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007091877A (ja) | 2005-09-29 | 2007-04-12 | Fujifilm Corp | ナフタロシアニン色素およびその製造方法 |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| JP2010500353A (ja) | 2006-08-08 | 2010-01-07 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | E1活性化酵素のインヒビターとして有用なヘテロアリール化合物 |
| JP2011513334A (ja) | 2008-02-29 | 2011-04-28 | ワイス・エルエルシー | ピラゾロ[1,5−a]ピリミジンの架橋二環式複素環式またはスピロ二環式複素環式誘導体、その調製方法および使用 |
| JP2011520941A (ja) | 2008-05-23 | 2011-07-21 | ノバルティス アーゲー | キノキサリン−およびキノリン−カルボキシアミド誘導体 |
| JP2012528194A (ja) | 2009-05-29 | 2012-11-12 | メルク・シャープ・アンド・ドーム・コーポレーション | C型肝炎などの疾患を処置するための3つの整列型アリール部分で構成された抗菌性化合物 |
| JP2013529658A (ja) | 2010-06-28 | 2013-07-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン |
| JP2015516424A (ja) | 2012-05-09 | 2015-06-11 | ゾエティス・エルエルシー | 駆虫剤としてのアゼチジン誘導体 |
| JP2016514134A (ja) | 2013-03-11 | 2016-05-19 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Betブロモドメイン阻害剤およびこれを用いる治療方法 |
| JP2016530231A (ja) | 2013-06-25 | 2016-09-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 脊髄性筋萎縮を処置するための化合物 |
| JP2017520570A (ja) | 2014-06-25 | 2017-07-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 脊髄性筋萎縮症を処置するためのイミダゾ[1,2−a]ピラジン−1−イルベンズアミド化合物 |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| CN104341403A (zh) | 2014-10-10 | 2015-02-11 | 山东盛华电子新材料有限公司 | 一种2,5-二杂环取代萘基噁烷衍生物及其制备方法 |
| WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| WO2019079649A1 (en) | 2017-10-18 | 2019-04-25 | Blueprint Medicines Corporation | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE |
| CN109180690A (zh) | 2018-10-15 | 2019-01-11 | 烟台显华化工科技有限公司 | 一类用作蓝色荧光材料的氮杂芳香化合物及其应用 |
Non-Patent Citations (7)
| Title |
|---|
| Barsu, Nagaraju et al.,Site-selective C-H bond carbonylation with CO2 and cobalt-catalysis,Catalysis Science & Technology,2018年,8(22),5963-5969. |
| Havens, Mallory A. et al.,Targeting RNA splicing for disease therapy,Wiley Interdisciplinary Reviews: RNA,2013年,4(3),247-266. |
| Lu, Xueyi et al.,Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach,Bioorganic & Medicinal Chemistry,2016年,24(18),4424-4433. |
| Pais, Vania F. et al.,Preparation and pH-Switching of Fluorescent Borylated Arylisoquinolines for Multilevel Molecular Logic,Journal of Organic Chemistry,2013年,78(16),,7949-7961. |
| REGISTRY(STN)[online],2012.09.18[検索日 2025.01.13] CAS登録番号 1394621-61-4 |
| Srivastava, Sanjay K. et al.,Synthesis and antifilarial profile of 5-amino and 5,8-diamino isoquinoline derivatives: a new class of antifilarial agents,Bioorganic & Medicinal Chemistry Letters,1996年, 6(22),2623-2628. |
| Suzuki, Takanori et al.,Preparation, properties, and X-ray structures of 5,5'-bi(8-aminoquinoxalyl)s: novel Wurster-type electron donors with a heterobiaryl skeleton,Tetrahedron Letters ,2004年,45(2),329-333. |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024532422A (ja) * | 2021-08-30 | 2024-09-05 | リミックス セラピューティクス インコーポレイテッド | スプライシングを調整するための化合物及び方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7736700B2 (ja) | 複素環アミド及びスプライシングを調節するためのその使用 | |
| JP7797407B2 (ja) | スプライシングを調節するための化合物及び方法 | |
| TWI912305B (zh) | 調節剪接之化合物及方法 | |
| KR20220157407A (ko) | 핵산 스플라이싱을 조절하기 위한 피리다진 유도체 | |
| AU2021228770A1 (en) | Thiophenyl derivatives useful for modulating nucleic acid splicing | |
| IL299543A (en) | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases | |
| IL311132A (en) | Splicing Modulation Compounds and Methods | |
| KR20260047325A (ko) | 스플라이싱을 조절하기 위한 화합물 및 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240227 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250214 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250513 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250711 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20250814 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250825 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251125 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260123 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260303 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260401 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7847852 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |